Overview

erlotinib


'erlotinib' can also refer to...

erlotinib

erlotinib

erlotinib n.

Erlotinib in cancer treatment

Response of malignant thymoma to erlotinib

Erlotinib-associated dermatological toxicity

Economic Analysis: Erlotinib Marginally Cost-Effective

Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study†

NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib

Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

348P“Metronomic” chemotherapy plus erlotinib, vinorelbini for unresectable or metastatic cutaneous squamous cell carcinoma

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

 

More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics

GO

Show Summary Details

Quick Reference

An small-molecule (423 Da) inhibitor of the EGF-receptor type-1 tyrosine kinase (HER1) that has been used to treat non-small-cell lung cancer. TN Tarceva.

Subjects: Clinical Pharmacology and Therapeutics.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.